Meet the 15 physician-scientists selected in 2007 as new HHMI investigators.

Vivian Cheung, MD 
University of Pennsylvania School of Medicine
Philadelphia, PA

Vivian Cheung wants to create a genetic test to predict patients’ individual responses to the most commonly prescribed therapeutics.

Arul M. Chinnaiyan, MD, PhD
University of Michigan Medical School
Ann Arbor, MI

Arul Chinnaiyan is searching for chromosomal abnormalities that drive the formation of solid tumors, with the ultimate goal of improving the early diagnosis and therapy of common cancers.

George Daley, MD, PhD
Children's Hospital Boston
Boston, MA

Through his studies of hematopoietic stem cells, George Daley is working toward improving drug and transplantation therapies for patients with bone marrow disease.

Elizabeth C. Engle, MD
Children's Hospital Boston
Boston, MA

Elizabeth Engle is studying how errors in the growth and development of motor neurons can create complex eye-movement disorders.

Erol Fikrig, MD
Yale University School of Medicine
New Haven, CT

Erol Fikrig is studying the relationship between pathogens, the vectors that carry them, and the hosts they infect, and looking for ways to interrupt those relationships to prevent or treat disease.

Joseph G. Gleeson, MD
University of California, San Diego School of Medicine
La Jolla, CA

Through his interactions with patients in the United States and the Middle East, Joseph Gleeson is working to understand the factors the brain needs to develop properly and the genetic mutations that can interfere with brain development.

Daniel Haber, MD, PhD
Massachusetts General Hospital
Boston, MA

Daniel Haber is investigating gene mutations that influence cancers' susceptibility to molecularly targeted cancer therapies as well as the genetics of the pediatric kidney cancer Wilms' tumor.

Friedhelm Hildebrandt, MD 
University of Michigan Medical School
Ann Arbor, MI

Friedhelm Hildebrandt is searching for genes responsible for childhood kidney diseases, enlisting the aid of thousands of patients worldwide.

S. Ananth Karumanchi, MD
Beth Israel Deaconess Medical Center
Boston, MA

S. Ananth Karumanchi is studying the molecular defects that lead to preeclampsia and using this knowledge to find ways to prevent and treat the disease.

Beth C. Levine, MD
University of Texas Southwestern Medical School at Dallas
Dallas, TX

Beth Levine is investigating the role of autophagy in cancer, infectious diseases, and autoimmune diseases to determine whether the process might be targeted for disease treatment.

Christopher V. Plowe, MD
University of Maryland Medical School
Baltimore, MD

Christopher Plowe studies the molecular evolution of malaria and the pathogen's response to vaccines and drug treatment, using his findings to extend the useful life of antimalarial drugs to treat patients in Africa and to develop malaria vaccines.

Kerry J. Ressler, MD, PhD
Emory University School of Medicine
Atlanta, GA

Kerry Ressler is using new knowledge about the molecular neurobiology of emotional learning to understand and treat fear and stress-related disorders in human patients.

David H. Rowitch, MD, PhD
University of California, San Francisco School of Medicine
San Francisco, CA

David Rowitch is working to understand how problems that arise during development, particularly among the glial cells that support neurons in the brain, can lead to cerebral palsy.

Charles L. Sawyers, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Charles Sawyers is investigating the signaling pathways that drive the growth of cancer cells, with an eye toward designing new treatment options for patients with chronic myeloid leukemia, prostate cancer, and glioblastoma.

Andrey Shaw, MD
Washington University School of Medicine in St. Louis
St. Louis, MO

Andrey Shaw is searching for genetic mutations that cause chronic kidney disease by interfering with the kidney’s ability to filter proteins from the blood.

For More Information

Jim Keeley 301.215.8858